The content on this site is intended for healthcare professionals only
Dr Zeina Nahleh speaks to ecancer about the OlympiA study.
Initially, she talks about the background and methodology of the study. Dr Nahleh then explains the key results of this study.
She concludes by discussing the future impact this study can have on treating and screening BRCA mutated breast cancer.
Watch the meeting in full by following the links below:
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer
Comment: EBCC 2024 highlights
Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours
Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients
Zanidatamab, palbociclib and fulvestrant show positive results in treating HER2+/HR+ mBC
Toripalimab and metronomic chemotherapy show efficacy in treating in HER2-negative metastatic breast cancer
